Log in

Relevant bibliographies by topics / Antipsychotic drugs. Diabetes

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Antipsychotic drugs. Diabetes'

Author: Grafiati

Published: 4 June 2021

Last updated: 3 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antipsychotic drugs. Diabetes.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antipsychotic drugs. Diabetes"

1

Taylor, David, Corina Young, Raadiyya Esop, Carol Paton, and Rebecca Walwyn. "Testing for diabetes in hospitalised patients prescribed antipsychotic drugs." British Journal of Psychiatry 185, no. 2 (August 2004): 152–56. http://dx.doi.org/10.1192/bjp.185.2.152.

Full text

Abstract:

BackgroundStudies using computer databases suggest that atypical antipsychotic agents are more likely to be associated with diabetes than are conventional drugs.AimsTo discover the extent of testing for diabetes mellitus in hospital in-patients prescribed antipsychotics.MethodPrescription charts were screened to identify patients prescribed antipsychotics. Case notes were then searched for evidence of testing for diabetes.ResultsIn all, 606 patients were prescribed antipsychotics, of whom 250 (41.3%) had evidence of prior testing for diabetes. Patients prescribed atypicals were 40% more likely to have been tested than those prescribed conventional drugs (RR = 1.4, 95% C11.1–1.9). Adjusted odds ratios v. conventional antipsychotics for testing were significantly higher for clozapine (OR = 4.64, 95% C12.42–8.90), olanzapine (OR= 1.85, 95% C11.04–3.30) and antipsychotic polypharmacy (OR= 2.96, 95% C11.59–5.52).ConclusionsTesting for diabetes was undertaken in less than half of the patients studied. Testing was more common in those receiving atypical antipsychotics. Apparent differences in claimed causal association of the use of some antipsychotics with diabetes may in part reflect different rates of testing.

APA, Harvard, Vancouver, ISO, and other styles

2

Kessing, Lars Vedel, Anders Frøkjær Thomsen, Ulla Brasch Mogensen, and Per Kragh Andersen. "Treatment with antipsychotics and the risk of diabetes in clinical practice." British Journal of Psychiatry 197, no. 4 (October 2010): 266–71. http://dx.doi.org/10.1192/bjp.bp.109.076935.

Full text

Abstract:

BackgroundTreatment with antipsychotics seems to increase the risk of developing diabetes but the association is poorly characterised in clinical practice.AimsTo investigate and characterise the incidence of diabetes for people treated with antipsychotic medication in clinical practice.MethodThe study used the linkage of registers of all prescribed antipsychotics, antidiabetics and diagnoses of diabetes in Denmark during a period from 1996 to 2005 and identified all people treated with antipsychotics in Denmark and a random sample of about 30% of the total Danish population.ResultsIn total, 345 937 patients who purchased antipsychotics and 1 426 488 unexposed individuals were included in the study. Among the total population, 50 379 individuals subsequently developed incident diabetes. Compared with unexposed individuals, treatment with first- (rate ratio, RR = 1.53, 95% CI 1.49–1.56) as well as second-generation (RR = 1.32, 95% CI 1.22–1.42) antipsychotics was associated with increased risk of subsequent incident diabetes. The rate of incident diabetes varied substantially between individual second-generation antipsychotic drugs (olanzapine, risperidone clozapine compared with unexposed individuals: low to moderate rate ratio between 1.17 and 1.57; ziprasidone and sertindol: two or more times increased rate ratio; amisulpride, quetiapine and aripiprazole: no significantly increased rate ratio). For both first- and second-generation antipsychotics, the incidence of diabetes increased with the number of prescriptions. Additionally, the incidence of diabetes increased with the number of combined antipsychotic drugs.ConclusionsIn clinical practice, treatment with first- and second-generation antipsychotics is associated with an increased risk of developing incident diabetes with large differences between individual drugs. The risk increases with the duration of treatment and with polypharmacy of antipsychotic drugs.

APA, Harvard, Vancouver, ISO, and other styles

3

Proietto, Joseph. "Diabetes and antipsychotic drugs." Australian Prescriber 27, no. 5 (October 1, 2004): 118–19. http://dx.doi.org/10.18773/austprescr.2004.098.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

M, Jagadeesan, Kiran Kumar R, and Justin Jacob Abraham. "A CASE STUDY ON SCHIZOPHRENIA INDUCED MULTIPLE COMORBIDITIES." Asian Journal of Pharmaceutical and Clinical Research 11, no. 6 (June 7, 2018): 1. http://dx.doi.org/10.22159/ajpcr.2018.v11i6.23979.

Full text

Abstract:

Schizophrenia is a mental disorder characterized by abnormal social behavior which includes false beliefs, confusion, and auditory hallucination. Antipsychotic drugs therapy increases the risk of developing diabetes mellitus and coronary artery disease (CAD) in schizophrenic patients. Hence, we have planned for a systematic approach toward the management of comorbidities induced in schizophrenic patients. A case study was conducted in 42-year-old female patient diagnosed with schizophrenia along with Type-2 diabetes mellitus, hypothyroidism, diabetic retinopathy, diabetic nephropathy, systemic hypertension, CAD-acute coronary syndrome recent inferior wall myocardial infarction. The patient was treated with atypical antipsychotics, antiplatelets, antianginals, statins, hypoglycemic agents, and other supportive measures. The patient improved symptomatically. The antipsychotic treatment for schizophrenia induces abnormal metabolic syndrome which results in decreased glucose and lipid metabolism that leads to obesity, hyperglycemia, and dyslipidemia associated with cardiovascular risks. Often antipsychotics are combined with benzodiazepines and antiparkinson agents to reduce the risks caused from large doses of antipsychotic medication. However, people receiving first-generation antipsychotics have higher prevalence of developing diabetes mellitus and cardiac risks compared to second-generation antipsychotics. Hence, we conclude that atypical antipsychotic drugs such as amisulpride, aripiprazole, and ziprasidone should be given to schizophrenic patients because these drugs have little effects on abnormal metabolic syndrome when compared to other antipsychotics. There is a need for proper screening of blood glucose level and cardiovascular risks assessment before the administration of antipsychotic medications to schizophrenic patients and also during the course of treatment regularly.

APA, Harvard, Vancouver, ISO, and other styles

5

Livingstone, C., and H. Rampes. "Atypical antipsychotic drugs and diabetes." Practical Diabetes International 20, no. 9 (2003): 327–31. http://dx.doi.org/10.1002/pdi.552.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Henderson, Valerie. "Atypical antipsychotic drugs and diabetes." Practical Diabetes International 20, no. 9 (2003): 331. http://dx.doi.org/10.1002/pdi.553.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Abdelmawla, Nasser, and Alex J. Mitchell. "Sudden cardiac death and antipsychotics Part 2: Monitoring and prevention." Advances in Psychiatric Treatment 12, no. 2 (March 2006): 100–109. http://dx.doi.org/10.1192/apt.12.2.100.

Full text

Abstract:

Cardiac safety of antipsychotic drugs continues to be a concern for both typical and atypical antipsychotics. Risk appears greatest in those with pre-existing cardiac disease but many patients may have occult cardiovascular disease. In addition, several drugs appear to increase the likelihood of diabetes and weight gain, which may have an additive adverse effect. On the basis of risk of sudden cardiac death and risk of QTc prolongation we suggest considering antipsychotics in two categories – higher and lower risk. Of most concern is the use of large cumulative doses of antipsychotics that are sometimes given inadvertently by different prescribers. Clinicians need to be aware how to read an ECG, and how to monitor physical parameters and interpret the significance of QTc prolongation in relation to antipsychotic prescribing. We suggest provisional guidance on antipsychotic monitoring in relation to cardiac safety but acknowledge that future studies will help clarify which antipsychotic drugs and which concomitant risk factors are most important for those with and without established cardiac disease.

APA, Harvard, Vancouver, ISO, and other styles

8

Bottai, T., P. Quintin, and E. Perrin. "Antipsychotics and the risk of diabetes: A general data review." European Psychiatry 20, S4 (December 2005): S349—S357. http://dx.doi.org/10.1016/s0924-9338(05)80190-7.

Full text

Abstract:

AbstractRecently, attention has focused on a potential link between schizophrenia and diabetes, with speculation that this potential associationis stronger in patients who are prescribed atypical antipsychotics. Pharmacoepidemiological studies can help to evaluate this potential association. Source data on the incidence of diabetes in patients treated with antipsychotics is available in the FDA MedWatch database, prescription claims databases and other patient registries. These data indicate that antipsychotic drugs may increase the risk of developing diabetes and that there may be an interaction with age. However, current data are insufficient to accurately assess potential differences in the risk of diabetes between users of individual antipsychotic medications. In addition, antipsychotic treatment-emergent diabetes has several distinct features, notably relating to age of onset, gender ratio, rate of deterioration of glycaemic control, and independence from initial treatment emergent weight gain. Nonetheless, guidelines for the control of risk factors for diabetes developed for the general population appear to be applicable to patients with schizophrenia.

APA, Harvard, Vancouver, ISO, and other styles

9

Tournier, M., A. Cougnard, B. Bégaud, A. Thiébaut, and H. Verdoux. "The Metabolic Impact of the Antipsychotic Drugs in Patients with Bipolar Disorder." European Psychiatry 24, S1 (January 2009): 1. http://dx.doi.org/10.1016/s0924-9338(09)70490-0.

Full text

Abstract:

Objective:To assess the metabolic impact of adding an antipsychotic to a mood stabilizer or switching a mood stabilizer to an antipsychotic in patients with bipolar disorder.Methods:A retrospective fixed cohort study was conducted through the claims database of the French health care program for the self-employed workers. The study population consisted of 3.172 patients age 18 and over who were exposed to mood stabilizers (i.e. lithium, valproate) a 3 month-period in 2004 without dispensing of non-sedative antipsychotic, antidiabetic or lipid-lowering drugs. The outcome was the occurrence of a metabolic incident over the follow-up period, using the dispensing of an antidiabetic drug as a marker of diabetes and the dispensing of a lipid-lowering drug as a marker of hypercholesterolemia or hypertriglyceridemia. A Cox proportional hazard model was used to assess the metabolic impact of the antipsychotics; using mood stabilizers as a reference. Antipsychotic exposition was stratified in «current» and «recent» (discontinued for less than 6 months) at the time of the metabolic incident.Results:196 patients (6.2%) received a first-generation antipsychotic, 352 (11.1%) a second-generation antipsychotic, 565 (17.8%) a sedative antipsychotic and 367 patients (11.6%) presented with a metabolic incident over the study period. The recent dispensing of a second-generation antipsychotic was associated with the occurrence of a metabolic incident [HR 2.1 (95%CI 1.2-3.7) p=0.006], while current dispensing or dispensing of first-generation antipsychotics were not.Conclusion:Second-generation antipsychotics have a metabolic impact compared to classic mood stabilizers in patients with bipolar disorder.

APA, Harvard, Vancouver, ISO, and other styles

10

Ananth, Jambur, Smitha Kolli, Sarath Gunatilake, and Steven Brown. "Atypical antipsychotic drugs, diabetes and ethnicity." Expert Opinion on Drug Safety 4, no. 6 (October 28, 2005): 1111–24. http://dx.doi.org/10.1517/14740338.4.6.1111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Antipsychotic drugs. Diabetes"

1

Yang, Min. "Antipsychotic drug utilization patterns and treatment-emergent diabetes: a methodological comparison of incidence using a claims database." Thesis, 2006. http://hdl.handle.net/2152/2648.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Harrington, Patricia Margaret. "Incident diabetes associated with second-generation antipsychotic therapy : an evaluation of the impact of dose and treatment indication." 2006. http://hdl.handle.net/2152/12997.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Cohn, Tony A. "Diabetes susceptibility in drug-free schizophrenia patients and metabolic changes after second generation antipsychotic treatment." 2006. http://link.library.utoronto.ca/eir/EIRdetail.cfm?Resources__ID=442102&T=F.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Antipsychotic drugs. Diabetes"

1

Barthel, Andreas, and Michael Bauer. Psychotropic drugs and metabolic risk. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198789284.003.0011.

Full text

Abstract:

Increased appetite and weight gain represent a significant problem related with particular antipsychotic drugs, antidepressants, mood stabilizers, and—to a lesser extent—anxiolytic drugs. Psychotropic drug-induced weight gain may contribute to obesity-related metabolic changes and pathological conditions such as dyslipidaemia, type-2-diabetes and hypertension—summarized as the metabolic syndrome—with an increased risk for cardiovascular morbidity and mortality. Interestingly, psychotropic drugs are also used for the treatment of diabetes-related complications. For example, antidepressants are effective for the treatment of neuropathic pain in patients with diabetic neuropathy. Therefore, it is essential to thoroughly balance potential benefits and risks in an individual patient to ensure drug safety and optimize the clinical outcome. In addition to diet and exercise, selection of psychotropic drugs and dose adjustment based on regular clinical follow-up visits is the key for the prevention and management of psychotropic drug induced weight gain in clinical practice.

APA, Harvard, Vancouver, ISO, and other styles

2

1967-, Bermudes Richard A., Keck Paul E, and McElroy Susan L, eds. Managing metabolic abnormalities in the psychiatrically ill: A clinical guide for psychiatrists. Washington, DC: American Psychiatric Pub., 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

(Editor), Richard A. Bermudes, Paul E. Keck (Editor), and Susan L. McElroy (Editor), eds. Managing Metabolic Abnormalities in the Psychiatrically Ill: A Clinical Guide for Psychiatrists. American Psychiatric Publishing, Inc., 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Cohn, Tony A. Diabetes susceptibility in drug-free schizophrenia patients and metabolic changes after second generation antipsychotic treatment. 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Antipsychotic drugs. Diabetes"

1

Vancampfort, Davy, Richard I. G. Holt, Brendon Stubbs, Marc De Hert, Katherine Samaras, and Alex J. Mitchell. "Type 2 Diabetes Mellitus." In Life-Threatening Effects of Antipsychotic Drugs, 255–78. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-12-803376-0.00012-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Baptista, Trino. "Antipsychotic Drugs, Weight Gain, and Diabetes." In Pharmacotherapy of Obesity, 69–83. CRC Press, 2004. http://dx.doi.org/10.1201/9780203508756.ch4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

"Antipsychotic Drugs, Weight Gain, and Diabetes." In Pharmacotherapy of Obesity, 93–110. CRC Press, 2004. http://dx.doi.org/10.1201/9780203508756-12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

DAGOGOJACK, S. "New Drugs and Diabetes Risk: Antipsychotic and Antiretroviral Agents." In Clinical Diabetes, 569–81. Elsevier, 2006. http://dx.doi.org/10.1016/b978-1-4160-0273-4.50047-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Davis, Julian R. E. "Hyperprolactinaemic anovulation." In Oxford Textbook of Endocrinology and Diabetes, 1224–29. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199235292.003.0846.

Full text

Abstract:

Prolactin is a polypeptide hormone, named from its well-known effects to promote lactation. It is essential for successful reproduction in man and mammals, although it is known to have a wide variety of nonreproductive effects whose clinical significance remains uncertain. Hyperprolactinaemia, reflecting sustained overproduction of lactin by the pituitary, is relatively common in the population. The commonest cause is the use of drugs that have dopamine D2 receptor antagonist activity (e.g. antipsychotic agents such as phenothiazines), pregnancy and lactation are the commonest physiological causes, and short-term acute stress, such as the anxiety provoked by blood sampling, is also a frequent cause of transient rises in serum prolactin that may be misinterpreted and necessitate a second confirmatory blood sample. Pathological pituitary causes of hyperprolactinaemia may reflect a functioning pituitary prolactinoma, but in many cases no adenoma is detectable on scanning, in which case the condition is termed idiopathic or nontumoral hyperprolactinaemia. The typical clinical features that suggest hyperprolactinaemia are those of galactorrhoea and oligo-/amenorrhoea. Weight gain has been reported in hyperprolactinaemic women, as has insulin resistance. Serum prolactin levels are readily measured by most clinical biochemistry laboratories, and prolactin levels should be measured on more than one occasion, with persistent unexplained hyperprolactinaemia requiring evaluation. Patients with hyperprolactinaemia may require treatment for various reasons, including restoration of ovulatory function, maintenance of adequate oestrogenization, suppression of galactorrhoea, or reduction in size of a mass lesion. Depending on the presentation and underlying cause, there are several treatment options; the main current treatment option is dopamine agonist therapy, surgery and (rarely) radiotherapy are also used in the treatment of prolactinomas.

APA, Harvard, Vancouver, ISO, and other styles

6

Singh, Panwar. "Chapter-08 Drugs used in psychiatric disorders: Antipsychotics." In Advances in Diabetes: Novel Insights, 316–20. Jaypee Brothers Medical Publishers (P) Ltd., 2016. http://dx.doi.org/10.5005/jp/books/12744_56.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Mandrioli, Roberto, Michele Protti, and Laura Mercolini. "Metabolic Syndrome in Schizophrenia: Focus on the Role of Antipsychotic Medications and Indications for Therapeutic Drug Monitoring (TDM) Methods." In Frontiers in Clinical Drug Research-Diabetes and Obesity, 1–65. BENTHAM SCIENCE PUBLISHERS, 2020. http://dx.doi.org/10.2174/9781681087535120050003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antipsychotic drugs. Diabetes"

1

Greene, Charlotte, Hanna Ward-Penny, Sarah Wild, and Caroline Jackson. "P68 Antidepressant and antipsychotic drug prescribing and complications of diabetes: a systematic review of observational studies." In Society for Social Medicine Annual Scientific Meeting Abstracts. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/jech-2021-ssmabstracts.156.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!